+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030

  • ID: 5201299
  • Report
  • September 2020
  • Region: Global
  • 223 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3M
  • Confab
  • Horizon Pharmaceuticals
  • M2M Pharmaceuticals
  • One Pharma
  • Sciarra Laboratories
  • MORE

Overview

Over the past few decades, the prevalence of respiratory disorders has been increasing at an alarming rate. In fact, each year around 7 million deaths are attributed to respiratory disorders caused by air pollution, worldwide.Moreover, as per a Global Burden of Disease study, around 3 million fatalities are reported annually due to chronic obstructive pulmonary disorders (COPD). It is also important to note that, as of April 2020, an estimated 330 million individuals are suffering from asthma.Other causative factors responsible for respiratory diseases include smoking, climate change, low immunity, inappropriate development of lungs, and bacterial, viral and fungal infections.It is worth mentioning that the novel SARS-CoV2 viral strain is a respiratory pathogen.

Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases/disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide). As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and/or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRA™ (migraine), NUMBRINO™ (local anesthetic), GIMOTI™ (diabetic gastroparesis), VALTOCO® (epilepsy), NAYZILAM® (epilepsy), DUAKLIR® PRESSAIR® (COPD), PROAIR® DIGIHALER™ (asthma and COPD), AIRDUO® DIGIHALER™ (asthma), SPRAVATO® (depression).

Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges.Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target. These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion/thickening, narrowing/collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine. Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development. Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years.

Scope of the Report

The ‘Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 – 2030’ report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain.

Amongst other elements, the report includes:

  • A detailed assessment of the overall landscape of companies offering contract and custom services for the inhaled and Intranasal drug development and manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, type of service provider (contract manufacturing organization and contract research organization), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of drug molecule (small molecule and biologic), type of inhaled and intranasal related primary service(s) offered (development, manufacturing, analytical testing/services, device selection/optimization and fill/finish and packaging), type of inhaled and intranasal related secondary service(s) offered (process development, pre-formulation development, formulation development, pre-formulation manufacturing, formulation manufacturing, particle engineering, product characterization, extractable and leachable studies, stability testing and plume geometry measurement), type of formulation (powder, aerosol and liquid), type of dosage form (metered dose inhaler, dry powder inhaler, nebulizer, soft mist inhaler, nasal spray, nasal drops, nasal powder and others), route of administration (oral and intranasal inhalation) and installed capacity and batch size (if available).
  • A detailed assessment of the overall landscape of the companies offering contract services for the inhaled and intranasal drug delivery system manufacturing, along with information on a number of relevant parameters, such as year of establishment, company size, scale of operation (precommercial and commercial), location of headquarters, location of manufacturing facilities, type of inhaled and intranasal drug delivery system related service(s) offered (design, development, manufacturing, assembly, fill/finish and packaging), type of formulation (powder, aerosol and liquid) and type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer, nasal spray and others).
  • A competitiveness analysis of inhaled and intranasal drug product contract service providers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration service strength (number of services offered, type of formulation(s) offered and route of administration), manufacturing strength (type of drug molecule, scale of operation, number of manufacturing facilities), supplier strength (company size and its experience in this field) and company size (small-sized, mid-sized and large).
  • Tabulated profiles of some of the key contract manufacturers (shortlisted based on a proprietary criterion) that offer a diverse range of capabilities for the development, manufacturing and packaging of inhaled and intranasal drugs across North America, Europe and Asia-Pacific. Each profile features an overview of the company, along with information related to its financial performance (if available), service portfolio, products and intranasal related capabilities, type of drug molecule, type of dosage form, inhaled and intranasal products related manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of the various partnerships related to inhaled and intranasal contract service providers, which have been established since 2015, based on several parameters, such as year of agreement, type of partnership (development agreements, manufacturing agreements, merger and acquisition, licensing agreement, commercialization, research and development agreements, service alliance, joint venture and other agreements), scale of operation (preclinical, clinical and commercial), type of inhaled and intranasal related service(s) offered (development, manufacturing, analytical testing/services and fill/finish and packaging), type of dosage form (metered dose inhalers, dry powder inhalers, nebulizers and others) and most active players. It also provides the regional distribution of the players involved in the collaborations.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by inhaled and intranasal product developers, while deciding whether to manufacture their respective products in-house or engage a contract service provider.
  • An estimate of the global, inhaled and intranasal product demand, based on the type of product (inhaled and intranasal), type of drug delivery system used (metered dose inhalers, dry powder inhalers, nebulizers and nasal sprays) and key geographical regions (North America, Europe and Asia-Pacific).
  • An insightful discussion on the impact of COVID-19 outbreak on the inhaled and intranasal service providers. In addition, it features various strategies that different companies have adopted/may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as overall pulmonary market, global intranasal drug market, cost of goods sold and outsourcing trends, we have provided an informed estimate of the likely evolution of the contract service providers market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] scale of operation (clinical, commercial and both), [B] type of product manufacturing services offered (API manufacturing, end product manufacturing and others), [C] type of drug delivery system used (metered dose inhaler, dry powder inhaler, nebulizer and nasal spray), [D] route of administration (orally inhaled and intranasal) and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In addition, specific to intranasal service providers, the market has been segmented by the type of drug class (corticosteroids, decongestants, antiallergic, anti-infectives and other topical preparations) and for inhalation service providers, the market has been segmented by the type of disease indication (asthma, COPD, diabetes, cystic fibrosis and others). In addition to the market forecast for inhaled and intranasal drugs, we have also provided a 10-year forecast for inhaled and intranasal drug delivery systems, covering the market of metered dose inhaler, dry powder inhaler, nebulizer and nasal spray. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Ben Forbes (Professor, King’s College London)
  • Dries Cardoen (Team Leader of Study Directors, Nelson Laboratories)
  • Neeraj Kumar (Honorary Secretary, The Indian Pharmaceutical Association)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading contract service providers offering inhalable and intranasal products related services, across the world?
  • In which regions are majority of the inhaled and intranasal product related manufacturing facilities located?
  • What percentage of inhaled and intranasal manufacturing operations are outsourced?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What is the impact of COVID-19 outbreak on inhaled and intranasal product services market?
  • What is the current, global demand for inhaled and intranasal products?
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M
  • Confab
  • Horizon Pharmaceuticals
  • M2M Pharmaceuticals
  • One Pharma
  • Sciarra Laboratories
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Inhaled and Intranasal Therapy
3.3. Types of Inhalable and Intranasal Drug Formulations
3.4. Types of Inhalable and Intranasal Drug Delivery Systems Formulations
3.4.1. Pressurized Metered Dose Inhalers
3.4.2. Dry Powder Inhalers
3.4.3. Nebulizers
3.4.4. Metered Spray Pumps / Intranasal Sprays
3.4.5. Aqueous Droplet Inhalers
3.5. Assessment of Quality and Performance During Inhalable and Intranasal Drug Development
3.6. Regulatory Landscape
3.7. Approved Inhaled and Intranasal Therapeutics Available in Developed Markets (the US and UK)
3.8. Importance of Outsourcing Inhaled and v Product Development Operations
3.9. Future Perspectives

4. INHALED AND INTRANASAL DRUG PRODUCT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Inhaled and Intranasal Drug Product Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size
4.2.4. Analysis by Type of Service Provider
4.2.5. Analysis by Company Size and Type of Service Provider
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Location of Headquarters
4.2.8. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.9. World Map: Analysis by Inhaled and Intranasal Drug Product Manufacturing Facilities
4.2.10. Analysis by Type of Drug Molecule
4.2.11. Analysis by Type of Inhaled and Intranasal Drug Product Related Primary Service(s) Offered
4.2.12. Analysis by Type of Inhaled and Intranasal Drug Product Related Secondary Service(s) Offered
4.2.13. Analysis by Type of Formulation
4.2.14. Analysis by Type of Dosage Form
4.2.15. Analysis by Route of Administration
4.2.16. Information on Production Capacity

5. INHALED AND INTRANASAL DRUG DELIVERY SYSTEM MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size
5.2.4. Analysis by Scale of Operation
5.2.5. Analysis by Location of Headquarters
5.2.6. Analysis by Location of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities
5.2.7. Analysis by Type of Inhaled and Intranasal Drug Delivery System Manufacturing Service(s) Offered
5.2.8. Analysis by Type of Formulation
5.2.10. Analysis by Type of Drug Delivery Systems

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers
6.3.1. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in North America
6.3.2. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in Europe
6.3.3. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers based in Asia-Pacific and Rest of the World
6.4. Inhaled and Intranasal Drug Product Contract Research Service Providers
6.4.1. Inhaled and Intranasal Drug Product Contract Research Service Providers based in North America
6.4.2. Inhaled and Intranasal Drug Product Contract Research Service Providers based in Europe
6.4.3. Inhaled and Intranasal Drug Product Contract Research Service Providers based in Asia-Pacific and Rest of the World
6.5. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers
6.5.1. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in North America
6.5.2. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in Europe
6.5.3. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers based in Asia-Pacific and Rest of the World

7. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Capsugel
7.2.1. Recent Developments and Future Outlook
7.3. Catalent
7.3.1. Recent Developments and Future Outlook
7.4. DPT Laboratories (A Mylan Company)
7.4.1. Recent Developments and Future Outlook
7.5. Kindeva Drug Delivery (Formerly 3M Drug Delivery Systems)
7.5.1. Recent Developments and Future Outlook

8. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC
8.1. Chapter Overview
8.2. Beximco Pharmaceuticals
8.2.1. Recent Developments and Future Outlook
8.3. Colep
8.3.1. Recent Developments and Future Outlook
8.4. Hovione
8.4.1. Recent Developments and Future Outlook
8.5. Orion
8.5.1. Recent Developments and Future Outlook
8.6. Quotient Sciences
8.6.1. Recent Developments and Future Outlook
8.7. Recipharm
8.7.1. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Inhaled and Intranasal Contract Research and Manufacturing Service Providers:
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Inhaled and Intranasal Drug Product Related Service(s) Offered
9.3.5. Analysis by Type of Formulation
9.3.6. Analysis by Type of Drug Delivery Systems Used
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Geographical Analysis
9.3.8.1. Intercontinental and Intracontinental Agreements

10. MAKE VERSUS BUY DECISION MAKING
10.1. Chapter Overview
10.2. Assumptions and Parameter Definitions
10.2.1. Scenario 1
10.2.2. Scenario 2
10.2.3. Scenario 3
10.2.4. Scenario 4
10.3. Concluding Remarks

11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global Demand for Inhaled and Intranasal Drug Delivery Systems, 2020-2030
11.3.1. Analysis by Route of Administration
11.3.2. Analysis by Type of Drug Delivery Systems Used
11.3.3. Analysis by Geographical Location

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030
12.3.1. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Scale of Operation, 2020-2030
12.3.2. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Type of Inhaled and Intranasal Drug Product Related Service, 2020-2030
12.3.3. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Type of Drug Delivery Systems Used, 2020-2030
12.3.4. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Route of Administration, 2020-2030
12.3.5. Inhaled and Intranasal Drug Product Contract Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030
12.4. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations, 2020-2030
12.4.1. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations: Distribution by Type of Disease Indication, 2020-2030
12.5. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations, 2020-2030
12.5.1. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations: Distribution by Type of Drug Class, 2020-2030
12.6. Overall Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030
12.6.1. Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market: Distribution by Type of Drug Delivery System Used, 2020-2030
12.6.2. Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market: Distribution by Route of Administration, 2020-2030
12.6.3. Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market: Distribution by Key Geographical Regions, 2020-2030

13. IMPACT OF COVID-19 PANDEMIC ON THE INHALED AND INTRANASAL SERVICE PROVIDERS MARKET
13.1 Chapter Overview
13.2. Current Opinions and Recuperative Initiatives of Key Players
13.2.1. Catalent
13.2.2. Hovione
13.2.3. Lonza
13.2.4. Quotient Sciences
13.2.5. Recipharm
13.3. Impact on Inhaled and Intranasal Product Service Providers Market
13.4. Recuperative Strategies for Contract Service Providers
13.4.1. Strategies for Implementation in the Short / Mid Term
13.4.2. Strategies for Implementation in the Long Term

14. CONCLUSION
14.1. Chapter Overview

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. King’s College London
15.2.1. Organization Snapshot
15.2.2. Interview Transcript: Ben Forbes, Professor
15.3. Nelson Laboratories
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Dries Cardoen, Team Leader of Study Directors
15.4. The Indian Pharmaceutical Association
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Neeraj Kumar, Honorary Secretary

16. APPENDIX 1: TABULATED DATA

Note: Product cover images may vary from those shown
3 of 4
  • 3M
  • 3P innovation
  • Actelion Pharmaceuticals
  • Aerami Therapeutics (formerly Dance Biopharm)
  • Aerosol Research and Engineering Laboratories
  • Akums Drugs & Pharmaceuticals
  • Alcami
  • Alpic Biotech
  • Altaris Capital Partners
  • Altimmune
  • Amneal Pharmaceuticals
  • Aptar Pharma
  • Arch Biopartners
  • Arcturus Therapeutics
  • ASM Aerosol-Service
  • Aspen Pharmacare
  • AstraZeneca
  • Atossa Therapeutics
  • Aurohealth
  • Basic Pharma
  • Battelle
  • Bespak
  • Beximco Pharmaceuticals
  • BioCare Group
  • Biofilms Research Center for Biointerfaces, Malmö University
  • Boehringer Ingelheim
  • Breath Therapeutics
  • Capsugel
  • Carclo Technical Plastics
  • Catalent
  • CF PharmTech
  • Charles River Laboratories
  • Chemic Laboratories
  • Chiesi Farmaceutici
  • Chromcore Lifesciences
  • Cirrus Pharmaceuticals
  • COC Farmaceutici
  • Colep
  • Confab
  • Consort Medical
  • Contract Pharmaceuticals
  • Creative Biolabs
  • Circassia
  • CrystecPharma
  • Curida
  • CytoAgents
  • Dalton Pharma Services
  • DFE Pharma
  • Doctor Pack
  • Dorizoe Lifesciences
  • DPT Laboratories
  • Dr. Reddy’s Laboratories
  • DRK Pharma Solutions
  • Dwarkesh Pharmaceuticals
  • EKG Life Science Solutions
  • Elfin Drugs
  • Emmace Consulting
  • Ennaid Therapeutics
  • Ethris
  • Eurofins
  • Evoke Pharma
  • Evonik
  • Experic
  • Farbe Firma
  • FAMAR
  • Focus Inhalation
  • Forefront Medical Technology
  • Forest Laboratories
  • Genentech
  • Gerresheimer
  • Getron Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline
  • Global Pharma
  • Hikma Pharmaceuticals
  • Horizon Pharmaceuticals
  • Hovione
  • Humanigen
  • Iconovo
  • IIT Research Institute (IITRI)
  • Impopharma
  • Importfab
  • Inhalexpert
  • InhaTarget Therapeutics
  • Insmed
  • Intas Pharmaceuticals
  • Intertek
  • Invion
  • iPharma
  • ITC Farma
  • J Pharmaceuticals
  • Jabil
  • Jagotec
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • Kiel University
  • Kindeva Drug Delivery
  • King’s College London
  • Kymos Pharma Services
  • Labiana Pharmaceuticals
  • Lamda Laboratories
  • Lannet Technologies
  • LEAX Group
  • Lepharm
  • Life Vision Healthcare
  • Lindal Group
  • Liquidia Technologies
  • Lomapharm
  • Lonza
  • Lovelace Biomedical
  • Lxir Medilabs (A unit of SMM Life Sciences)
  • M2M Pharmaceuticals
  • Macter International
  • Malmö University
  • MannKind
  • Mapaex
  • Maya Biotech
  • McMaster University
  • Medicair Bioscience Laboratories
  • Medicilon
  • Medlab Pharmaceuticals
  • MedPharm
  • Menarini Group
  • Merck
  • Micro-Sphere
  • MidasCare
  • Mipharm
  • MMG Healthcare
  • Moderna Therapeutics
  • Molex
  • Medicon Valley Inhalation Consortium (MVIC)
  • Mylan
  • Nanologica
  • Nanopharm
  • Napp Pharmaceuticals
  • Nelipak Healthcare Packaging
  • Nelson Laboratories
  • Nemera
  • Nephron Pharmaceuticals
  • Neurelis
  • Neurimmune
  • Newtec Pro Manufacturing
  • Next Breath
  • Nipro
  • Nitto Medic
  • Nivon Specialties
  • Noble
  • Novartis
  • One Pharma
  • Orion
  • Oté Pharma
  • Optinose
  • Paragon Nordic
  • PARI Pharma
  • PCI Pharma Services
  • Penta Arzneimittel
  • Pfizer
  • Pharma Stulln
  • Pharma Tech
  • PharmaCielo
  • Pharmaserve
  • Pharmaterials
  • PHAST (Acquired by Eurofins)
  • Phillips-Medisize
  • Pine Lake Laboratories
  • Polyphor
  • PPD Laboratories
  • Probiotec
  • Propeller Health
  • Proveris Scientific
  • Pulmatrix
  • PulmoFlow
  • Pursuit Pharma
  • Pushkar Pharma
  • Quotient Sciences
  • Recipharm
  • Renaissance Pharmaceuticals
  • Roche
  • Rommelag
  • Rubicon Research
  • S.R.Chemicals and Pharmaceuticals
  • SAFE Pharmaceutical
  • Salvat
  • Sandoz
  • Sanofi
  • Sciarra Laboratories
  • Seikagaku
  • Sentiss Pharma
  • Servier Pharmaceuticals
  • SHL Group
  • Simpler Consulting
  • SkyePharma
  • Smithers
  • Spicona
  • Stabicon Life Sciences
  • Stevanato Group
  • Summit Biosciences
  • Sunovion
  • Sunovion Pharmaceuticals
  • Synerlab
  • Takeda
  • Teva Pharmaceuticals
  • The Indian Pharmaceutical Association
  • The Ritedose Corporation
  • Theravance Biopharma
  • Tinuum
  • Toxikon
  • Trillium Health Care Products
  • UCB Pharma
  • Ultratech India
  • United Therapeutics
  • University of Birmingham
  • University of Copenhagen
  • University of Cyprus
  • University of Florida
  • University of Turku
  • Bausch Health (formerly Valeant Pharmaceuticals)
  • Vectura
  • ViralClear Pharmaceuticals (A subsidiary of BioSig Technologies)
  • Vinventions
  • Vivimed
  • West Coast Pharmaceutical
  • Westmed Medical Group
Note: Product cover images may vary from those shown
4 of 4

 

 

Loading
LOADING...

Adroll
adroll